Nexalin Technology Inc. Total Liabilities

Latest as of June 2026: $1.48 Million USD

Nexalin Technology Inc. total liabilities. Based on the latest financial reports, Nexalin Technology Inc. (NXL) has total liabilities worth $1.48 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Nexalin Technology Inc. liquidity resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Nexalin Technology Inc. (2019–2025)

Total liabilities of Nexalin Technology Inc. from 2019 to 2025. This chart illustrates how Nexalin Technology Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Nexalin Technology Inc. to see how much of total assets are deployed in long-term investments.

Nexalin Technology Inc. Competitors by Total Liabilities

The table below lists competitors of Nexalin Technology Inc. ranked by their total liabilities.

Company Country Total Liabilities
Inotiv Inc
NASDAQ:NOTV
USA $625.32 Million
Kezar Life Sciences Inc
NASDAQ:KZR
USA $2.76 Million
MEP Infrastructure Developers Limited
NSE:MEP
India Rs35.65 Billion
Magnetite Mines Ltd
AU:MGT
Australia AU$4.31 Million
Biomx Inc
NYSE MKT:PHGE
USA $15.68 Million
Uniinfo Telecom Services Limited
NSE:UNIINFO
India Rs99.34 Million
MFC Industrial Real Estate Investment Trust
BK:MIT
Thailand ฿139.44 Million
Baroyeca Gold & Silver Inc
V:BGS
Canada CA$304.13K

Liability Composition Analysis (2019–2025)

This chart breaks down Nexalin Technology Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Nexalin Technology Inc.'s balance sheet.

Liquidity & Leverage Metrics

Nexalin Technology Inc. Total Liabilities Ratios Explained

Nexalin Technology Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.25 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.98 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.49 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Nexalin Technology Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Nexalin Technology Inc. (2019–2025)

The table below shows the annual total liabilities of Nexalin Technology Inc. from 2019 to 2025.

Year Total Liabilities Change
2025-12-31 $887.33K +62.31%
2024-12-31 $546.69K +28.55%
2023-12-31 $425.28K -78.23%
2022-12-31 $1.95 Million -19.80%
2021-12-31 $2.44 Million +42.54%
2020-12-31 $1.71 Million +32.27%
2019-12-31 $1.29 Million --

About Nexalin Technology Inc.

NASDAQ:NXL USA Medical Devices
Market Cap
$1.25 Million
Market Cap Rank
#30505 Global
#6216 in USA
Share Price
$1.51
Change (1 day)
-5.94%
52-Week Range
$0.25 - $7.55
All Time High
$7.55
About

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 a… Read more